David Stack is the CEO of Pacira BioSciences, Inc., a role he's held since 2010. With a background in Business Administration and over three decades in the pharmaceutical industry, he has guided the company through significant growth. In 2023, Stack's...

David Stack is the CEO of Pacira BioSciences, Inc., a role he's held since 2010. With a background in Business Administration and over three decades in the pharmaceutical industry, he has guided the company through significant growth. In 2023, Stack's total compensation reached over $6.8 million, which included a salary, bonus, and stock options. His leadership has notably driven record sales for EXPAREL, a non-opioid pain management product, reflecting a commitment to improving healthcare practices.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Pacira BioSciences, Inc. CEOs

P

David Stack

Ex-CEO of Pacira BioSciences, Inc.

Education

Bachelor's degree in Business Administration

Field of Expertise

Healthcare & Life Sciences - Pharmaceuticals

Sector of Economy

Healthcare

Born

January 1, 1962 - 63 years ago

CEO of Pacira BioSciences, Inc. for

13 years 2 months (Oct 2010 - Dec 2023)

Previous Experience

Chief Executive Officer of Pacira Pharmaceuticals, Inc. since 2010; previously held senior leadership roles at various pharmaceutical companies.

Rivals

Competitors/colleagues of David Stack

Holdings

See how much did David Stack make over time.

As of now, David Stack has a substantial stock position in Pacira BioSciences, Inc., which has seen strong fluctuations. In recent years, his insider trading noted a peak holding value of around $26.8 million in July 2020, during strong company...

As of now, David Stack has a substantial stock position in Pacira BioSciences, Inc., which has seen strong fluctuations. In recent years, his insider trading noted a peak holding value of around $26.8 million in July 2020, during strong company performance. His holdings have generally tracked the increasing market interest in Pacira’s innovative products. Notably, in 2023, Stack's stock worth fluctuated around $15 million, marking a significant personal investment in the company's vision and growth.

Loading...

Total Stock Sold

$47.85M

PCRX

$47.85M

900,290 PCRX shares

What if they kept their stock?

If David Stack didn't sell their stock, today they would have:
Extra PCRX900,290 shares worth $42.24M.
This is -11.73% and $5.61M less than what they got when they sold the stock.

Charitable Transactions

PCRX

6,080 shares

PCRX

Recent Charitable Transactions

PCRX

1,080 shares

PCRX

Mar 24, 2021

Charity

PCRX

2,000 shares

PCRX

Dec 31, 2013

Charity

PCRX

3,000 shares

PCRX

Dec 31, 2011

Charity

Insider Trading

See recent insider trades of David Stack.

PCRX

32,700 shares

PCRX

Jun 14, 2023

Received

PCRX

$399.04K

PCRX at $38.43/share

Jun 6, 2023

Sale

PCRX

$1.57M

PCRX at $60.81/share

Jun 6, 2022

Sale

PCRX

21,500 shares

PCRX

Jun 6, 2022

Received

PCRX

17,800 shares

PCRX

Jun 9, 2021

Received

PCRX

$909.76K

PCRX at $61.04/share

Jun 4, 2021

Sale

PCRX

$2.61M

PCRX at $61.44/share

Mar 24, 2021

Sale

PCRX

1,080 shares

PCRX

Mar 24, 2021

Charity

PCRX

$2.98M

PCRX at $70.04/share

Feb 2, 2021

Sale

PCRX

$4.98M

PCRX at $55.36/share

Oct 14, 2020

Sale

Compensation History

See how much did David Stack make over time.

In 2023, David Stack earned a total of $6,878,091. His base salary was set at $941,387, with bonuses tied to performance metrics like sales and product development. He also vested stock units worth around $934,470. His compensation is designed to align with shareholder interests, meaning that it rises or falls based on the company's success. This structure demonstrates how his pay is linked closely to the strategic goals of Pacira.

Year

2023

Total Compensation

$2.64M

Salary

$941.39K

Board Justification

The compensation program aims to attract, retain, and motivate executives, aligning their interests with those of stockholders through performance-based incentives.

Bonus

$720.60K

Board Justification

Annual incentive payment of 90% of target based on operational and financial performance for 2023.

Other

$39.52K

Board Justification

Includes health, dental, vision, disability, and group term life insurance premiums paid by the company.

Restricted Stock

$934.47K(24.08K RSU)

Board Justification

24,075 shares of RSUs vested in 2023, valued at $934,470.

Performance Metrics

Performance metrics include operational and financial goals, with a focus on net product sales and adjusted EBITDA.

Other Pacira BioSciences, Inc. CEOs

Here are other CEOs of Pacira BioSciences, Inc.

Frank Lee

CEO of Pacira BioSciences, Inc.

January 2024 - Present